The era of CFTR modulators: improvements made and remaining challenges

The entry into the clinic of CFTR modulators such as TRIKAFTA has significantly improved life for ∼90% CF patients carrying one or two F508del mutations but challenges remain for rare CFTR mutations and the management of lung infections @SaraOcana1 https://bit.ly/3aRafQF

Detalles Bibliográficos
Autores principales: Cuevas-Ocaña, Sara, Laselva, Onofrio, Avolio, Julie, Nenna, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714553/
https://www.ncbi.nlm.nih.gov/pubmed/33304402
http://dx.doi.org/10.1183/20734735.0016-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714553/
https://www.ncbi.nlm.nih.gov/pubmed/33304402
http://dx.doi.org/10.1183/20734735.0016-2020

Ejemplares similares